Vertex Pharma (VRTX): VX-661/Kalydeco Combo Fails But Was A Long Shot - Baird
- Wall Street again marks new highs in post-election run
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- After-Hours Stock Movers 12/08: (FNSR) (AVGO) (GLPG) Higher; (XTLY) (RH) (DLTH) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) as the company followed in Orkambi's footsteps when the VX-661/ivacaftor failed to show a benefit in patients heterozygous for the F508del mutation and a mutation resulting in minimal CFTR function (F508del het/mins).
The analyst had been skeptical from the start, but the next-gen triple combos are expected to move into Phase 2 soon. This is an effort the analyst is far more enthusiastic about for this subgroup of CF patients.
No change to the price target of $128.
Shares of Vertex closed at $102.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Cuts Price Target on Comtech Telecom (CMTL) to $16 Following 1Q
- UPDATE: Stifel Downgrades CEB Inc (CEB) to Hold
- FBR Capital Raises Price Target on TEGNA (TGNA) Following Investor Conference
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!